In Low-Level Laser Therapy (LLLT) choosing the proper laser wavelength is extremely important. In this article, we have investigated the effects of four different laser wavelengths on oxidant parameters (AGE, AOPP, and ox-LDL) levels in diabetic Wistar rats experimentally. At first, 24 rats were divided into six equal groups. Except for the none diabetic control group, the other five groups received streptozotocin (STZ) injection to induce diabetes. Four groups of diabetic rats were then irradiated by four different laser wavelengths IR (808nm), Red (638nm), Green (532nm) and Blue (450nm). The last group which did not receive any irradiation is named non-irradiated diabetic control group. Laser therapies were performed Intravenously through an animal's caudal vein by a fiber Optics. Finally, the levels of oxidant parameters in rat's blood samples of each group were discussed. Results show a decrease in oxidants levels in all four irradiated groups of rats relative to the non-irradiated diabetic control group. More importantly, shorter wavelengths affect more efficient than longer wavelengths on reducing the oxidants levels with constant Laser energy. As a result, we conclude that laser with shorter wavelength e.g. Blue is more effective than longer wavelengths e.g. IR or Red, in reducing the oxidant parameters (AGE, AOPP, and ox-LDL) levels in Intravenous LLLT.
| Published in | International Journal of Clinical and Experimental Medical Sciences (Volume 6, Issue 2) |
| DOI | 10.11648/j.ijcems.20200602.11 |
| Page(s) | 17-24 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2020. Published by Science Publishing Group |
Laser Therapy, Diabetes, Oxidants, AGEs, AOPP, Ox-LDL
| [1] | S. A. Al-Maweri, B. Kalakonda, N. A. AlAizari, W. A. Al-Soneidar, S. Ashraf, S. Abdulrab, E. S. Al-Mawri, Efficacy of low-level laser therapy in management of recurrent herpes labialis: a systematic review, Lasers in medical science 33 (7) (2018) 1423–1430. |
| [2] | P. R. King, Low level laser therapy: A review, Lasers in Medical Science 4 (3) (1989) 141. |
| [3] | Z. Sharifian, M. Bayat, M. Alidoust, R. M. Farahani, M. Bayat, F. Rezaie, H. Bayat, Histological and gene expression analysis of the effects of pulsed low-level laser therapy on wound healing of streptozotocin-induced diabetic rats, Lasers in medical science 29 (3) (2014) 1227–1235. |
| [4] | S. B. Alinca, E. Saglam, N. O. Kandas, O. Okcu, N. Yilmaz, B. Goncu, M. A. Dogan, Comparison of the efficacy of low-level laser therapy and photodynamic therapy on oral mucositis in rats, Lasers in medical science (2019) 1–9. |
| [5] | D. Atlas, International diabetes federation, IDF Diabetes Atlas, 7th edn. Brussels, Belgium: International Diabetes Federation. |
| [6] | S. Wild, G. Roglic, A. Green, R. Sicree, H. King, Global prevalence of diabetes: estimates for the year 2000 and projections for 2030, Diabetes care 27 (5) (2004) 1047–1053. |
| [7] | E. Ko¸cak, M. Sa˘glam, S. A. Kayı¸s, N. Du¨ndar, L. Kebap¸cılar, B. G. Loos, S. S. Hakkı, Nonsurgical periodon- tal therapy with/without diode laser modulates metabolic control of type 2 diabetics with periodontitis: a randomized clinical trial, Lasers in medical science 31 (2) (2016) 343–353. |
| [8] | H. A. Kahn, R. Hiller, Blindness caused by diabetic retinopathy, American journal of ophthalmology 78 (1) (1974) 58–67. |
| [9] | C. for Disease Control, P. (CDC, et al., Blindness caused by diabetes–massachusetts, 1987-1994., MMWR. Morbidity and mortality weekly report 45 (43) (1996) 937. |
| [10] | L. A. Lavery, D. C. Lavery, T. L. Quebedeax-Farnham, Increased foot pressures after great toe amputation in diabetes, Diabetes Care 18 (11) (1995) 1460–1462. |
| [11] | D. Ziegler, Type 2 diabetes as an inflammatory cardiovascular disorder, Current molecular medicine 5 (3) (2005) 309–322. |
| [12] | P. J. Dyck, J. Karnes, P. O’Brien, P. Thomas, A. Asbury, A. Winegrad, D. Porte, Diabetic neuropathy. |
| [13] | J. L. Gross, M. J. De Azevedo, S. P. Silveiro, L. H. Canani, M. L. Caramori, T. Zelmanovitz, Diabetic nephropathy: diagnosis, prevention, and treatment, Diabetes care 28 (1) (2005) 164–176. |
| [14] | M. E. Molitch, R. A. DeFronzo, M. J. Franz, W. F. Keane, et al., Nephropathy in diabetes, Diabetes care 27 (2004) S79. |
| [15] | S. B. Rabelo, A. B. Villaverde, R. A. Nicolau, M. A. C. Salgado, M. D. S. Melo, M. T. T. Pacheco, Comparison between wound healing in induced diabetic and nondiabetic rats after low-level laser therapy, Photomedicine and Laser Therapy 24 (4) (2006) 474–479. |
| [16] | C. for Disease Control, Prevention, et al., National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the united states, 2011, Atlanta, GA: US department of health and human services, centers for disease control and prevention 201 (1) (2011) 2568–2569. |
| [17] | P. Chatterjee, A. K. Srivastava, D. A. Kumar, A. Chakrawarty, M. A. Khan, A. K. Ambashtha, V. Kumar, L. De Taboada, A. B. Dey, Effect of deep tissue laser therapy treatment on peripheral neuropathic pain in older adults with type 2 diabetes: a pilot randomized clinical trial, BMC geriatrics 19 (1) (2019) 218. |
| [18] | N. Kazemikhoo, A. Sarafnejad, F. Ansari, P. Mehdipour, Modifying effect of intravenous laser therapy on the protein expression of arginase and epidermal growth factor receptor in type 2 diabetic patients, Lasers in medical science 31 (8) (2016) 1537–1545. |
| [19] | R. Obradovi´c, L. Kesi´c, D. Mihailovi´c, S. Anti´c, G. Jovanovi´c, A. Petrovi´c, S. Peˇsevska, A histological evaluation of a low-level laser therapy as an adjunct to periodontal therapy in patients with diabetes mellitus, Lasers in medical science 28 (1) (2013) 19–24. |
| [20] | U. Asmat, K. Abad, K. Ismail, Diabetes mellitus and oxidative stressa concise review, Saudi Pharmaceutical Journal 24 (5) (2016) 547–553. |
| [21] | A. Maritim, a. Sanders, J. Watkins Iii, Diabetes, oxidative stress, and antioxidants: a review, Journal of biochemical and molecular toxicology 17 (1) (2003) 24–38. |
| [22] | A. Piwowar, M. Knapik-Kordecka, M. Warwas, Aopp and its relations with selected markers of oxidative/antioxidative system in type 2 diabetes mellitus, Diabetes research and clinical practice 77 (2) (2007) 188–192. |
| [23] | D. Bonnefont-Rousselot, Glucose and reactive oxygen species, Current Opinion in Clinical Nutrition & Metabolic Care 5 (5) (2002) 561–568. |
| [24] | J. Kuyvenhoven, A. Meinders, Oxidative stress and diabetes mellitus: pathogenesis of long-term complications, European Journal of Internal Medicine 10 (1) (1999) 9–19. |
| [25] | P. Mart´ın-Galla´n, A. Carrascosa, M. Gussiny´e, C. Dom´ınguez, Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications, Free Radical Biology and Medicine 34 (12) (2003) 1563–1574. |
| [26] | P. Dandona, K. Thusu, S. Cook, B. Snyder, J. Makowski, D. Armstrong, T. Nicotera, Oxidative damage to dna in diabetes mellitus, The Lancet 347 (8999) (1996) 444–445. |
| [27] | Z. Zheng, Y. Zeng, X. Zhu, Y. Tan, Y. Li, Q. Li, G. Yi, Apom-s1p modulates ox-ldl-induced inflammation through the pi3k/akt signaling pathway in huvecs, Inflammation (2018) 1–12. |
| [28] | S. Parthasarathy, A. Raghavamenon, M. O. Garelnabi, N. Santanam, Oxidized low-density lipoprotein, in: Free Radicals and Antioxidant Protocols, Springer, 2010, pp. 403–417. |
| [29] | S.-F. Li, Y.-W. Hu, J.-Y. Zhao, X. Ma, S.-G. Wu, J.-B. Lu, Y.-R. Hu, Y.-C. Wang, J.-J. Gao, Y.-H. Sha, et al., Ox-ldl upregulates crp expression through the igf2 pathway in thp-1 macrophages, Inflammation 38 (2) (2015) 576–583. |
| [30] | M. F. Lopes-Virella, G. Virella, T. J. Orchard, S. Koskinen, R. W. Evans, D. J. Becker, K. Y.-Z. Forrest, Antibodies to oxidized ldl and ldl-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus, Clinical Immunology 90 (2) (1999) 165–172. |
| [31] | R. Singh, A. Barden, T. Mori, L. Beilin, Advanced glycation end-products: a review, Diabetologia 44 (2) (2001) 129–146. |
| [32] | V. Jakuˇs, N. Rietbrock, Advanced glycation end-products and the progress of diabetic vascular complications, Physiological research 53 (2) (2004) 131–142. |
| [33] | M. Chang, B. Zhang, Y. Tian, M. Hu, G. Zhang, Z. Di, X. Wang, Z. Liu, N. Gu, Y. Liu, Ages decreased sirt3 expression and sirt3 activation protected ages-induced epcs dysfunction and strengthened anti-oxidant capacity, Inflammation 40 (2) (2017) 473–485. |
| [34] | L. C. de Vos, J. D. Lefrandt, R. P. Dullaart, C. J. Zeebregts, A. J. Smit, Advanced glycation end products: An emerging biomarker for adverse outcome in patients with peripheral artery disease, Atherosclerosis 254 (2016) 291–299. |
| [35] | A. Piwowar, Advanced oxidation protein products. part i. mechanism of the formation, characteristics and property, Polski merkuriusz lekarski: organ Polskiego Towarzystwa Lekarskiego 28 (164) (2010) 166–169. |
| [36] | G. V. Bochi, V. D. Torbitz, L. P. Cargnin, J. A. M. de Carvalho, P. Gomes, R. N. Moresco, An alternative pathway through the fenton reaction for the formation of advanced oxidation protein products, a new class of inflammatory mediators, Inflammation 37 (2) (2014) 512–521. |
| [37] | H. Mirmiranpour, F. S. Nosrati, S. O. Sobhani, S. Nazifi Takantape, A. Amjadi, Effect of low level laser irradiation on the function of glycated catalase, Journal of Lasers in Medical Sciences 9 (3) (2018) 212–218. |
| [38] | A. Amjadi, H. Mirmiranpour, S. O. Sobhani, N. Moazami Goudarzi, Intravenous laser wavelength radiation effect on lcat, pon1, catalase, and frap in diabetic rats, Lasers Med Sci (2019) https://doi.org/10.1007/s10103-019-02805-5 |
| [39] | M. Kalousova, J. Skrha, T. Zima, et al., Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus, Physiological research 51 (6) (2002) 597–604. |
| [40] | Purifine, Aké-Tano Sassor Odile, et al. "Macroangiopathy and Associated Factors in Outpatients with Type 2 Diabetes Attending the Antidiabetic Center of Abidjan in Ivory Coast." Science Journal of Public Health 5.4 (2017): 347. |
| [41] | Ma, Wuren, et al. "Complicated Effect of He-Ne Laser Therapy on Pro-/Anti-Inflammatory Cytokines from Serum in Rats." Animal and Veterinary Sciences 6.5 (2018): 88. |
| [42] | Moroianu, Lavinia Alexandra, et al. "Depression in Patients with Diabetes." |
| [43] | Papadopoulou, L., and F. Papoulia. "Depression and quality of life in patients with diabetes." American Journal of Nursing Science 4.2 (2015): 88. |
| [44] | Myint, Aye Aye, Kyaw Soe Win, and Zaw Aung. "Alzheimer’s disease and type 2 diabetes mellitus: Risk factors and effectiveness of antidiabetic agents in treatment of Alzheimer’s disease." SJCM 2.3 (2013): 114. |
APA Style
Hossein Mirmiranpour, Ahmad Amjadi, Salile Khandani, Yasaman Shafaee, Seyed Omid Sobhani. (2020). Wavelength Effect in Laser Therapy of Diabetic Rats on Oxidants: AGEs, AOPP, ox-LDL Levels. International Journal of Clinical and Experimental Medical Sciences, 6(2), 17-24. https://doi.org/10.11648/j.ijcems.20200602.11
ACS Style
Hossein Mirmiranpour; Ahmad Amjadi; Salile Khandani; Yasaman Shafaee; Seyed Omid Sobhani. Wavelength Effect in Laser Therapy of Diabetic Rats on Oxidants: AGEs, AOPP, ox-LDL Levels. Int. J. Clin. Exp. Med. Sci. 2020, 6(2), 17-24. doi: 10.11648/j.ijcems.20200602.11
AMA Style
Hossein Mirmiranpour, Ahmad Amjadi, Salile Khandani, Yasaman Shafaee, Seyed Omid Sobhani. Wavelength Effect in Laser Therapy of Diabetic Rats on Oxidants: AGEs, AOPP, ox-LDL Levels. Int J Clin Exp Med Sci. 2020;6(2):17-24. doi: 10.11648/j.ijcems.20200602.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijcems.20200602.11,
author = {Hossein Mirmiranpour and Ahmad Amjadi and Salile Khandani and Yasaman Shafaee and Seyed Omid Sobhani},
title = {Wavelength Effect in Laser Therapy of Diabetic Rats on Oxidants: AGEs, AOPP, ox-LDL Levels},
journal = {International Journal of Clinical and Experimental Medical Sciences},
volume = {6},
number = {2},
pages = {17-24},
doi = {10.11648/j.ijcems.20200602.11},
url = {https://doi.org/10.11648/j.ijcems.20200602.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcems.20200602.11},
abstract = {In Low-Level Laser Therapy (LLLT) choosing the proper laser wavelength is extremely important. In this article, we have investigated the effects of four different laser wavelengths on oxidant parameters (AGE, AOPP, and ox-LDL) levels in diabetic Wistar rats experimentally. At first, 24 rats were divided into six equal groups. Except for the none diabetic control group, the other five groups received streptozotocin (STZ) injection to induce diabetes. Four groups of diabetic rats were then irradiated by four different laser wavelengths IR (808nm), Red (638nm), Green (532nm) and Blue (450nm). The last group which did not receive any irradiation is named non-irradiated diabetic control group. Laser therapies were performed Intravenously through an animal's caudal vein by a fiber Optics. Finally, the levels of oxidant parameters in rat's blood samples of each group were discussed. Results show a decrease in oxidants levels in all four irradiated groups of rats relative to the non-irradiated diabetic control group. More importantly, shorter wavelengths affect more efficient than longer wavelengths on reducing the oxidants levels with constant Laser energy. As a result, we conclude that laser with shorter wavelength e.g. Blue is more effective than longer wavelengths e.g. IR or Red, in reducing the oxidant parameters (AGE, AOPP, and ox-LDL) levels in Intravenous LLLT.},
year = {2020}
}
TY - JOUR T1 - Wavelength Effect in Laser Therapy of Diabetic Rats on Oxidants: AGEs, AOPP, ox-LDL Levels AU - Hossein Mirmiranpour AU - Ahmad Amjadi AU - Salile Khandani AU - Yasaman Shafaee AU - Seyed Omid Sobhani Y1 - 2020/05/28 PY - 2020 N1 - https://doi.org/10.11648/j.ijcems.20200602.11 DO - 10.11648/j.ijcems.20200602.11 T2 - International Journal of Clinical and Experimental Medical Sciences JF - International Journal of Clinical and Experimental Medical Sciences JO - International Journal of Clinical and Experimental Medical Sciences SP - 17 EP - 24 PB - Science Publishing Group SN - 2469-8032 UR - https://doi.org/10.11648/j.ijcems.20200602.11 AB - In Low-Level Laser Therapy (LLLT) choosing the proper laser wavelength is extremely important. In this article, we have investigated the effects of four different laser wavelengths on oxidant parameters (AGE, AOPP, and ox-LDL) levels in diabetic Wistar rats experimentally. At first, 24 rats were divided into six equal groups. Except for the none diabetic control group, the other five groups received streptozotocin (STZ) injection to induce diabetes. Four groups of diabetic rats were then irradiated by four different laser wavelengths IR (808nm), Red (638nm), Green (532nm) and Blue (450nm). The last group which did not receive any irradiation is named non-irradiated diabetic control group. Laser therapies were performed Intravenously through an animal's caudal vein by a fiber Optics. Finally, the levels of oxidant parameters in rat's blood samples of each group were discussed. Results show a decrease in oxidants levels in all four irradiated groups of rats relative to the non-irradiated diabetic control group. More importantly, shorter wavelengths affect more efficient than longer wavelengths on reducing the oxidants levels with constant Laser energy. As a result, we conclude that laser with shorter wavelength e.g. Blue is more effective than longer wavelengths e.g. IR or Red, in reducing the oxidant parameters (AGE, AOPP, and ox-LDL) levels in Intravenous LLLT. VL - 6 IS - 2 ER -
Information
Email: